1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Sedana Medical AB

Sedana Medical AB

9.52
SEK
-0.39
(-3.94%)
-0.37EPS
822.51MMarket Cap
Oct 22Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.41
0.47
0.59
0.76
0.86
1.55
1.72
1.24
1.55
1.8
2.02
2.05
Basic EPS, GAAP
-0.02
0.02
-0.06
-0.09
-0.2
-0.3
-0.62
-0.74
-0.6
-0.11
-0.6
-0.37
Free Cash Flow per Basic Share
- -
-0.08
-0.37
-0.46
-0.73
-1.01
-1.63
-2.55
-2.08
-1.88
-0.76
-0.88
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.02
1.7
2.84
6.26
5.98
11.09
10.36
9.76
9.65
9.07
8.94
Tangible Book Value per Share
-0.01
-0.05
1.32
2.17
5.16
4.14
8.37
6.4
4.27
2.29
1.31
0.95
Basic Weighted Avg Shares
68
68
68
77
84
92
93
99
99
99
99
99
Sales/Revenue/Turnover
28
32
40
58
72
142
159
123
154
179
200
204
Operating Margin (%)
-4.93
0.85
-8.95
-14.76
-23.28
-15.19
-38.45
-84.59
-43.25
-28.41
-16.26
-15
Depreciation Expense
- -
- -
3
6
7
14
13
24
25
23
22
27
Net Income, GAAP
-1
1
-4
-7
-16
-27
-58
-74
-60
-11
-59
-37
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4.29
4
-9.59
-11.86
-22.86
-19.14
-36.42
-59.83
-38.74
-5.97
-29.59
-17.99
Working Capital
6
2
84
159
461
371
819
625
417
226
122
86
LT Debt
5
5
- -
1
1
5
5
4
1
3
2
3
Total Equity
- -
1
116
218
569
551
1,101
1,029
970
958
901
888
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
150.38
-6.59
-4.11
-4.16
-4.84
-7.02
-6.9
-5.96
-1.11
-6.37
-4.03

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
2
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
1,021
916
823

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
174
167
131
Cash, Cash Equivalents & STI
91
81
52
Accounts Receivable, Net
29
26
27
Inventories
38
44
43
Total Current Liabilities
52
58
45
Payables & Accruals
- -
- -
- -
ST Debt
3
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
963.25%
16.07%
-6%
Free Cash Flow
- -
8.65%
-59.74%
Net Income, GAAP
16.77%
98.89%
455.03%
Sales/Revenue/Turnover
24.78%
8.57%
12.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
49
41
40
49
179
2025
57
50
- -
52
200
2026
53
49
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
-0.17
-0.23
0.09
-0.11
2025
-0.24
-0.13
- -
-0.1
-0.6
2026
-0.04
-0.1
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Johannes Doll
Full Time Employees
122
Sector
Health technology
Industry
Medical specialties
Address
Svärdvägen 3A Danderyd AB Sweden 182 33
IPO Date
Jun 21, 2017
Website
sedanamedical.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation for mechanically ventilated patients in intensive care; it develops, manufactures, markets and sells medical devices and pharmaceuticals including the Sedaconda ACD (formerly AnaConDa), a disposable device for administering volatile anesthetics with high reflection efficiency, bacterial/viral filtration and heat/moisture exchange; Sedaconda ACD-L and ACD-S variants for longer and shorter durations; Sedaconda Syringe for precise agent delivery; Sedaconda (isoflurane) for adult sedation; scavenging products such as FlurAbsorb and FlurAbsorb-S carbon filters, Scavenging Tubes and mounts; gas monitoring equipment like the AMG-06 Gas Monitor for CO2 and anesthetic concentrations; and accessories including Dryline II Water Traps and gas sampling lines. The company conducts clinical development to expand applications, including pediatric use and US market entry targeting FDA approval and 2027 launch. Sedana Medical maintains direct sales in Benelux, France, Germany, Great Britain, Nordics and Spain, with distributors across other parts of Europe, Asia, Australia, Canada and South/Central America; founded in 2005, it is headquartered in Danderyd, Stockholm, Sweden, and listed on Nasdaq Stockholm (SEDANA.ST). In 2025, the company completed the acquisition of its main supplier Innovatif Cekal for 34 MSEK to enhance supply chain control and reduce costs of goods sold, a transaction announced in July 2024 and financed from cash reserves, expected to improve operational cash flow from 2025 onward.